Inflammatory muscle diseases

Neurology India

Volumn 56, Issue 3, 2008, Pages 263-270

  Mastaglia, F ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Dermatomyositis; Inclusion body myositis; Inflammatory myopathies; Pathogenesis; Polymyositis; Treatment

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ECULIZUMAB; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISOLONE; RITUXIMAB; TACROLIMUS;

CLINICAL TRIAL; DERMATOMYOSITIS; DRUG MECHANISM; DRUG SUBSTITUTION; DYSPHAGIA; HUMAN; IMMUNE DEFICIENCY; IMMUNOTHERAPY; INCLUSION BODY MYOSITIS; POLYMYOSITIS; REVIEW;

ANIMALS; DERMATOMYOSITIS; HUMANS; MYOSITIS; MYOSITIS, INCLUSION BODY; POLYMYOSITIS;

EID: 56049122443     PISSN: 00283886     EISSN: 19984022     Source Type: Journal    
DOI: 10.4103/0028-3886.43444     Document Type: Review

References (44)

1. Mastaglia FL. Inflammatory diseases of muscle. Oxford: Blackwell Scientific Publications; 1988.
2. Chimelli L. Infective myopathies. In: Mastaglia FL, Hilton-Jones D, editors. Handbook of Clinical Neurology: Myopathies. Amsterdam: Elsevier; 2007. p. 303-19.
3. Mastaglia FL, Garlepp MJ, Phillips BA, Zilko PJ. Inflammatory myopathies: Clinical, diagnostic and therapeutic aspects. Muscle Nerve 2003;27:407-25.
4. Needham M, James I, Corbett A, Day T, Christiansen F, Phillips B, et al. Sporadic inclusion body myositis: Phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry 2008;79:1056-60.
5. Mastaglia F, Price P, Walters S, Fabian V, Miller J, Zilko P. Familial inclusion body myositis in a mother and son with different ancestral MHC haplotypes. Neuromuscul Disord 2006;16:754-8.
6. Sivakumar K, Semino-Mora C, Dalakas MC. An inflammatory, familial, inclusion body myositis with autoimmune features and a phenotype identical to sporadic inclusion body myositis: Studies in three families. Brain 1997;120:653-61.
7. Argov Z, Mitrani-Rosenbaum S. Hereditary inclusion body myopathy and other rimmed vacuolar myopathies. In: Mastaglia FL, Hilton-Jones D, editors. Handbook of clinical neurology. Vol. 86. Amsterdam: Elsevier B.V.; 2007. p. 243-53.
8. Badrising UA, Maat-Schieman ML, van Houwelingen JC, van Doorn PA, van Duinen SG, van Engelen BG, et al. Inclusion body myositis: Clinical features and clinical course of the disease in 64 patients. J Neurol 2005;252:1448-54.
9. Phillips BA, Cala LA, Thickbroom GW, Melsom A, Zilko PJ, Mastaglia FL. Patterns of muscle involvement in inclusion body myositis: Clinical and magnetic resonance imaging study. Muscle Nerve 2001;24:1526-34.
10. Yazici Y, Kagen LJ. The association of malignancy with myositis. Curr Opin Rheumatol 2000;12:498-500.
11. Zantos D, Zhang Y, Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol 1994;21:1855-9.
12. Levin MI, Mozaffar T, Al-Lozi MT, Pestronk A. Paraneoplastic necrotizing myopathy: Clinical and pathological features. Neurology 1998;50:764-7.
13. Cupler EJ, Leon-Monzon M, Miller J, Semino-Mora C, Anderson TL, Dalakas MC. Inclusion body myositis in HIV-1 and HTLV-1 infected patients. Brain 1996;119:1887-93.
14. Needham M, Mastaglia FL. Inclusion body myositis: Current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007;6:620-31.
15. Mastaglia FL, Phillips BA. Idiopathic inflammatory myopathies: Epidemiology, classification, and diagnostic criteria. Rheum Dis Clin North Am 2002;28:723-41.
16. Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004;14:337-45.
17. Garlepp MJ, Mastaglia FL. Autoantibodies in inflammatory myopathies. Am J Med Sci 2000;319:227-33.
18. Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57:664-78.
19. Greenberg SA, Sanoudou D, Haslett JN, Kohane IS, Kunkel LM, Beggs AH, et al. Molecular profiles of inflammatory myopathies. Neurology 2002;59:1170-82.
20. Raju R, Dalakas MC. Gene expression profile in the muscles of patients with inflammatory myopathies: Effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 2005;128:1887-96.
21. Tezak Z, Hoffman EP, Lutz JL, Fedczyna TO, Stephan D, Bremer EG, et al. Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: A novel model of pathogenesis. J Immunol 2002;168:4154-63.
22. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971-82.
23. Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 2007;69:2008-19.
24. Greenberg SA, Bradshaw EM, Pinkus JL, Pinkus GS, Burleson T, Due B, et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 2005;65:1782-7.
25. Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies, II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984;16:209-15.
26. Goebels N, Michaelis D, Engelhardt M, Huber S, Bender A, Pongratz D, et al. Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest 1996;97:2905-10.
27. Blume G, Pestronk A, Frank B, Johns DR. Polymyositis with cytochrome oxidase negative muscle fibres: Early quadriceps weakness and poor response to immunosuppressive therapy. Brain 1997;120:39-45.
28. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008;70:418-24.
29. Needham M, Mastaglia FL. Sporadic inclusion body myositis: A continuing puzzle. Neuromuscul Disord 2008;18:6-16.
30. Askanas V, Engel WK. Inclusion-body myositis: A myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology 2006;66:S39-48.
31. Fratta P, Engel WK, Van Leeuwen FW, Hol EM, Vattemi G, Askanas V. Mutant ubiquitin UBB+1 is accumulated in sporadic inclusion-body myositis muscle fibers. Neurology 2004;63:1114-7.
32. Oldfors A, Moslemi AR, Jonasson L, Ohlsson M, Kollberg G, Lindberg C. Mitochondrial abnormalities in inclusion-body myositis. Neurology 2006;66:S49-55.
33. Mastaglia FL. When the treatment does not work: Polymyositis. Pract Neurol 2008;In press.
34. Nirmalananthan N, Holton JL, Hanna MG. Is it really myositis? A consideration of the differential diagnosis. Curr Opin Rheumatol 2004;16:684-91.
35. Baer AN. Advances in the therapy of idiopathic inflammatory myopathies. Curr Opin Rheumatol 2006;18:236-41.
36. Dalakas MC. Retroviruses and inflammatory myopathies in humans and primates. Baillieres Clin Neurol 1993;2:659-91.
37. Levine TD. Rituximab in the treatment of dermatomyositis: An open-label pilot study. Arthritis Rheum 2005;52:601-7.
38. Dalakas MC. Therapeutic targets in patients with inflammatory myopathies: Present approaches and a look to the future. Neuromuscul Disord 2006;16:223-36.
39. Baron F, Ribbens C, Kaye O, Fillet G, Malaise M, Beguin Y. Effective treatment of Jo-1-associated polymyositis with T-cell-depleted autologous peripheral blood stem cell transplantation. Br J Haematol 2000;110:339-42.
40. Cherin P, Pelletier S, Teixeira A, Laforet P, Simon A, Herson S, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 2002;58:326.
41. Walter MC, Lochmuller H, Toepfer M, Schlotter B, Reilich P, Schroder M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: A double-blind, placebo-controlled study. J Neurol 2000;247:22-8.
42. Lindberg C, Trysberg E, Tarkowski A, Oldfors A. Anti-T-lymphocyte globulin treatment in inclusion body myositis: A randomized pilot study. Neurology 2003;61:260-2.
43. Dalakas MC, Rakocevic G, McElroy B, Saljegheh M, Brookline MA, Love MH, et al. Alemtuzumab (CAMPATH 1-h) therapy in sporadic inclusion body myositis (sIBM): A treatment trial in patients with established natural history data. Neurology 2007;68:A361.
44. Barohn RJ, Herbelin L, Kissel JT, King W, McVey AL, Saperstein DS, et al. Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology 2006;66:S123-4.